Our mission - is to facilitate the transition of the Russian pharmaceutical market to develop into mature, be a guide on the course of development of the potential of all the pharmaceutical market participants, thereby improving the quality of life for the end user and society in general. Despite the relatively high susceptibility to Russia's external economic and financial risks, imbalances in the domestic policy and great social disparities, the pharmaceutical market in Russia has had a stable positive growth for the last few years.
Problems with the availability of the necessary children's dosage forms are created because of unreasonably tight regulatory and price pressures. This was announced during a session organized by RBC at the International Conference of Innovative Technologies and Discoveries in the Pharmaceutical Industry of INOPharma by Ivan Glushkov.
Market experts estimate the approved method of drug pricing differently: many pharmaceutical manufacturers positively assessed the changes, but some experts said that this tool to reduce the cost of drugs would cause some of them to leave the market.
The Ministry of Health has developed a bill that will oblige drug manufacturers who are on the list of vital and essential (Vital and Essential Drugs) to reduce prices. For example, it will be necessary to reduce the marginal selling price of an imported drug if its value has fallen in the country of production.
Analysts differed in market growth forecasts for 2018. During the RAFM meeting, three analytical companies presented their forecasts for the current year. If you make a rating in terms of their optimism, then the first place will undoubtedly get Alpharm.
The Ministry of Health has developed a bill that will oblige drug manufacturers who are on the list of vital and essential (Vital and Essential Drugs) to reduce prices. For example, it will be necessary to lower the marginal selling price of an imported drug if its value has fallen in the country of production.
The Basic Law of the European Union on the Regulation of the Circulation of Medicines for Medical Use - Directive 2001/83 / EC of the European Parliament and of the Council of November 6, 2001 on the Community Code on Medicinal Preparations for Medical Use - has been translated into Russian and published in open access
The Federal Antimonopoly Service (FAS) has prepared amendments to the Civil Code of the Russian Federation on the legalization of parallel imports. FAS proposes to launch the mechanism from 2021, allowing for a period of up to five years to import, without the consent of the right holders, certain groups of goods that meet one of four main criteria: if such products are not available in Russia, if they are not available in the domestic market, if the prices for goods are overpriced, finally, if they differ qualitatively from their counterparts sold in other countries.
According to the international analytical agency IQVIA, in the last few years in Russia there has been an increase in the use of drugs for the treatment of respiratory diseases, in particular, for the treatment of bronchial asthma and COPD.